retatrutide trials weight loss (“reta”) is an experimental weight-loss drug currently in Phase 3 clinical trials. It's a once-weekly injection similar to Ozempic and Mounjaro—but more powerful. The reason comes down to how it works retatrutide weight loss phase 2

This is not unusual and reflects the complex interplay of slowed gastric emptying (which promotes constipation) and altered intestinal motility (which can trigger diarrhea)

Semaglutide GLP-1 has been shown to reduce visceral adipose tissue, or belly fat, in patients with obesity

But the glucagon receptor is where retatrutide truly separates itself

Nausea is the single most common side effect of GLP-1 receptor agonist medications and the most common reason patients in clinical trials and in clinic discontinue treatment

The regulatory landscape and what it means for dosing The availability and dosage charts of these compounds are tied to their regulatory status, and that status affects everything from access to quality to clinical support